Smith Group Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Smith Group Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$489K	Buy	+2,900	New	+$430K	0.02%	147
2026 Q1	–	Sell	-2,642	Closed	-$375K	–	183
2025 Q4	$375K	Buy	2,642 +382	+17%	+$55.3K	0.02%	154
2025 Q3	$317K	Buy	+2,260	New	+$306K	0.02%	158
2024 Q2	–	Sell	-48,114	Closed	-$6.64M	–	171
2024 Q1	$6.64M	Sell	48,114 -20,340	-30%	-$2.78M	0.38%	70
2023 Q4	$9.02M	Buy	+68,454	New	+$7.88M	0.52%	67
2016 Q2	–	Sell	-17,720	Closed	-$701K	–	506
2016 Q1	$701K	Sell	17,720 -150	-0.8%	-$5.95K	0.02%	161
2015 Q4	$1.01M	Buy	+17,870	New	+$908K	0.03%	173

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Smith Group Asset Management's NBIX Position: Q2 2026 in Review

Smith Group Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,900 shares worth $489K. The stake represents 0.02% of the portfolio and ranks #147 among its holdings. This is a return to the name: Smith Group Asset Management previously reported a position in NBIX as recently as Q4 2025.

Smith Group Asset Management first reported a position in NBIX in Q4 2015 and has held it in 7 quarters since. The position peaked at $9.02M in Q4 2023. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Smith Group Asset Management held 2,900 shares of Neurocrine Biosciences worth $489K as of Q2 2026.
Neurocrine Biosciences was a new Smith Group Asset Management position in Q2 2026.
Neurocrine Biosciences made up 0.02% of Smith Group Asset Management's portfolio in Q2 2026, its #147 holding.
Smith Group Asset Management first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 7 quarters since.
Smith Group Asset Management's Neurocrine Biosciences position peaked at $9.02M in Q4 2023.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Smith Group Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.